Drugs / Lunacalcipol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01453634 | Jan → Jul 2013 | end stage renal failure, secondary hyperparathyroidism of renal origin | OPKO Health, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00742716 | Oct 2008 → Feb 2010 | chronic renal failure syndrome, secondary hyperparathyroidism of renal origin | OPKO IP Holdings II, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00384098 | Sep 2006 → May 2007 | psoriasis | OPKO Health, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lunacalcipol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01453634 ↗ |
| Known as | CTA018 | “A Randomized, Open Label, Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Injection in Subjects With Stage 5 Chronic Kidney...” NCT01453634 ↗ |
| Action | Activate | “Vitamin D receptor agonist” CHEMBL2105705 ↗ |
| Modality | Small molecule | — CHEMBL2105705 ↗ |
| Route | Topical | “Topically Applied CTA018” NCT00384098 ↗ |
| Target | VDR | “Vitamin D receptor agonist” CHEMBL2105705 ↗ |